Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Recursion Pharmaceuticals, Inc. Financials Banner

Recursion Pharmaceuticals, Inc. Financials

RXRX Stock Analysis

Page title

Section title

RXRX Income Statement Key Metrics

  • Revenue(TTM)65.18 M
  • Gross Profit(TTM)1.96 M
  • EBITDA(TTM)-366.27 M
  • Net Income(TTM)-377.58 M
  • EPS Diluted(TTM)-1.5299999999999998

Decode RXRX's Latest Earnings Call with Ease

Tap 'Generate' for a crystal-clear,
AI-crafted summary and stay ahead in the investment game!

RXRX earnings and revenue history

Gross Profit Margin vs Peers

Profit margin ratio of RXRX (-0.146) is lower than the average of its peers (0.038).

Net Profit Margin vs Peers

Net profit margin ratio of RXRX (-7.360) is lower than the average of its peers (-5.058).

RXRX Return on Equity

See how efficiently RXRX generates profit for it's shareholders.

-70.79%

10
0
100
  1. Poor

  2. Average

  3. Strong

Return on Equity vs Peers

Return on Equity ratio of RXRX (-0.708) is higher than the average of its peers (-0.896).

Return on Equity Growth

RXRX's Return on Equity has shown poor growth over the past 10 years, increasing by only -7.07%.

RXRX Revenue Growth

See how RXRX has grown it's revenue over the past 10 years.


Revenue Growth

RXRX's revenue has grown significantly over the past 10 years, increasing by over 91.94%.

RXRX FY, 2023 Revenue Breakdown

See how RXRX converts it's revenue into profit.

RXRX Balance Sheet Health

RXRX Balance Sheet Breakdown 2023

Assets

  1. Long Term Assets

  2. Cash & Equivalents

  3. Inventory

  4. Receivables

  5. Property Plant Equipments

  6. Others

Liabilities

  1. Short Term Debt

  2. Long Term Debt

  3. Account Payables

  4. Others

RXRX financial position analysis

Short Term Liabilities

RXRX's short term assets($438M) can safely cover it's short term liabilities($93M).

Long Term Liabilities

RXRX's short term assets($438M) can safely cover it's long term liabilities($97M).

RXRX Debt to Equity